MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Inclusion Criteria:

Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy
Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody

Measurable disease defined by at least one of the following:

Serum M-protein >/= 0.5 g/dL by SPEP
Urinary M-protein excretion >/= 200 mg/24 hours by UPEP
Serum immunoglobulin FLC >/= 10 mg/dL (>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
ECOG performance status 0 -1
Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade
Exclusion Criteria:

Active plasma cell leukemia
Amyloidosis
Stem cell transplant with 12 weeks prior to enrollment, or active GVHD
POEMS syndrome
Any active uncontrolled bacterial, fungal, or viral infection
Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment
Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)
Sub-Study A Only: Previous treatment with BCMA bispecific antibody
Sub-Study B Only: Previous treatment with BCMA directed therapy